Accumulationa nd aggregation of the intrinsically disordered protein a-synuclein (a-Syn) into amyloid fibrils are hallmarks of as eries of heterogeneous neurodegenerative disorders, known as synucleinopathies and most notably Parkinson's disease (PD). The crucial role of a-Syn aggregation in PD makes it an attractive targetf or the development of disease-modifying therapeutics that would inhibit a-Syn aggregation or disrupti ts preformed fibrillara ssemblies. To this end, we have designed and synthesized two naphthoquinone-dopamine-basedh ybrid small molecules, NQDA and Cl-NQDA, and demonstrated their abilityt oi nhibit in vitro amyloid formation by a-Syn using ThT assay,C D, TEM, and Congo red birefringence.M oreover, these hybrid molecules efficiently disassembled preformed fibrils of a-Syn into nontoxic species, as evident from LUV leakage assay. NQDA and Cl-NQDA were found to have low cytotoxicity andt hey attenuated the toxicityi nduced by a-Syn towards SH-SY5Y neuroblastoma cells. NQDA was found to efficiently cross an in vitro human blood-brain barrier model. These naphthoquinone-dopamine based derivativesc an be an attractive scaffold for therapeuticd esign towards PD.